Injections bypass this route entirely, delivering the nutrient directly into the bloodstream for immediate absorption
0.51ml every 34 days
Seven reconstitution mistakes that ruin tirzepatide Tirzepatide is a peptide
However, once it enters cancer cells, once inside cancer cells, high intracellular GSH concentrations cleave the disulfide bond, converting the cyclic peptide into its linear form
"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial"
How Tirzepatide Compares Mechanistically to Semaglutide and Liraglutide | Feature | Tirzepatide | Semaglutide | Liraglutide | |---|---|---|---| | Receptor targets | GIP-R + GLP-1R | GLP-1R only | GLP-1R only | | Half-life | ~5 days | ~7 days | ~13 hours | | Dosing frequency | Weekly | Weekly | Daily | | Max approved weight loss dose | 15 mg | 2.4 mg (Wegovy) | 3 mg (Saxenda) | | Mean weight loss (key trial) | 20.9% (SURMOUNT-1) | 14.9% (STEP-1) | 5.8% (SCALE) | | Biased GLP-1R agonism | Yes (low beta-arrestin) | Partial | Lower | | Adipose GIPR mechanism | Yes | No | No | The 6-percentage-point gap in mean weight loss between tirzepatide and semaglutide in their respective Phase III key trials reflects the additive adipose and hypothalamic contributions of GIPR engagement [34]
